Search
New York Paid Clinical Trials
A listing of 4476 clinical trials in New York actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
3517 - 3528 of 4476
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Location
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
New York is currently home to 4476 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Sevoflurane Concentrations in Children
Recruiting
The sevoflurane concentrations (as well as vital signs, child's date of birth, type of surgery) will be recorded during the first 10 minutes of anesthesia.
Gender:
ALL
Ages:
Between 2 years and 7 years
Trial Updated:
10/23/2024
Locations: John R. Oishei Children's Hospital, Buffalo, New York
Conditions: Anesthetic, Sevoflurane, Age
Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients
Recruiting
The trial aims to evaluate the efficacy of single agent L19IL2, single agent L19TNF, and combination L19IL2+L19TNF given concurrently with anti-PD1 therapy compared to historical control of anti-PD-1 re-challenge alone for anti-PD1 refractory unresectable stage III-IV melanoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/23/2024
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Melanoma Stage III, Melanoma Stage IV
Exactech Proximal Humerus Fracture Plate System Post Market Clinical Follow-up
Recruiting
The objective of this study is to collect and evaluate long-term clinical outcomes data in order to better understand the safety and performance of the Equinoxe Proximal Humerus Fracture Plates over time. This study will follow subjects for a period of up to 10 years post-surgery.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
10/23/2024
Locations: NYU Grossman School of Medicine, New York, New York
Conditions: Proximal Humeral Fracture, Fracture Dislocation, Non-Union Fracture
Clinical Study Evaluating Pharmacogenomics-informed Pharmacotherapy Versus Dosing As Usual in Psychiatric Disorders
Recruiting
A 24-week, patient- and rater-blinded, two-arm, parallel-group controlled, and multi-centre randomized clinical trial (RCT) to establish the benefits of pharmacogenetics-informed pharmacotherapy versus dosing as usual (DAU) in psychiatric patients suffering from mood, anxiety, or psychotic disorders.
Gender:
ALL
Ages:
Between 16 years and 65 years
Trial Updated:
10/23/2024
Locations: SUNY Upstate Medical University, Department of Psychiatry and Behavioural Sciences, Syracuse, New York
Conditions: Mood Disorders, Anxiety Disorders, Psychotic Disorders
Kaneka IED Coil System for the Treatment of Wide Necked Ruptured and Unruptured Intracranial Aneurysms
Recruiting
This is a multi-center, prospective, propensity matched twin armed study conducted on 50 patients in the experimental arm followed for 18 months after intervention evaluating cost effectiveness, safety and efficacy of therapy.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
10/23/2024
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Intracranial Aneurysms, Wide Neck Intracranial Aneurysms
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Recruiting
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interferes with the binding of beta-catenin to TBL1, which may help stop the growth of tumor cells by blocking the signals passed from one molecule to another inside a cell that tell a cell to grow.
Gender:
ALL
Ages:
Between 12 months and 30 years
Trial Updated:
10/23/2024
Locations: NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York
Conditions: Colorectal Carcinoma, Endometrial Carcinoma, Melanoma, Neuroblastoma, Ovarian Carcinoma, Pancreatic Ductal Adenocarcinoma, Recurrent Desmoid Fibromatosis, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Hepatocellular Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Refractory Desmoid Fibromatosis, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Hepatocellular Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Solid Pseudopapillary Neoplasm of the Pancreas, Wilms Tumor
Quantitative Susceptibility Mapping (QSM) to Guide Iron Chelating Therapy
Recruiting
The overall goal of this research is to help develop a new magnetic resonance (MR) method, Quantitative Susceptibility Mapping (QSM), to improve the measurement of liver iron concentrations without the need for a liver biopsy. Measurement of liver iron is important to diagnose and treat patients who have too much iron in their bodies (iron overload). Liver iron measurements by current MRI methods (R2 and R2\*) can be inaccurate because of the effects of fat, fibrosis and other abnormalities. QSM... Read More
Gender:
ALL
Ages:
2 years and above
Trial Updated:
10/23/2024
Locations: Weill Cornell Medical College, New York, New York
Conditions: MRI Scans
Sana Device for Post-Treatment Lyme Disease Syndrome Chronic Pain
Recruiting
This study will investigate the effectiveness of the Sana Pain Reliever (Sana PR) at reducing chronic pain.
The Sana PR is a device comprised of one main component (Mask with Earbuds) and two ancillary components (Charger and Headband). The device is worn over the eyes (with earbuds in ears). The device pulses light at a single wavelength but various frequencies throughout a specific firmware algorithm. Through the earbuds, the device also plays different tones in conjunction with the pulses. T... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/22/2024
Locations: The Cohen Center for Recovery from Complex Chronic Illnesses (CoRE), New York, New York
Conditions: Post-treatment Lyme Disease Syndrome, Chronic Pain
Aspirin and Hemocompatibility Events in Chronic Advanced Heart Failure Patients with Assist Device
Recruiting
Heart failure is a world epidemic. LVADs are increasingly used as they have demonstrated improved survival rates compared to optimal medical management. Improving outcomes have been seen with the newer LVAD technology, the HeartMate 3 (Abbott, Chicago, IL), however, hemocompatibility related adverse events, including thrombosis and bleeding, are still a major cause of morbidity and mortality. The recent ARIES trial showed that in patients with advanced heart failure treated with a HeartMate3 LVA... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/22/2024
Locations: Columbia Irving Medical Center, New York, New York
Conditions: Bleeding, Clot Blood
Vestibular Innovation in Pain
Recruiting
The VIP trial will assess the effectiveness, tolerability, and durability of effect of vestibulocortical stimulation (VCS) - a safe \& cost-effective bedside technique - in treating pain, fatigue \& related symptoms using validated patient-reported outcomes. Data from this trial will be used to guide optimized treatment protocols in future randomized controlled trials and help inform the implementation of VCS into standard clinical practice.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
10/22/2024
Locations: Mount Sinai West, New York, New York
Conditions: Pain, Fatigue, Quality of Life
Lamivudine for Solid Tumors
Recruiting
Single arm, set dose clinical trial of Lamivudine for Relapsed Refractory Solid Tumors.
Accrual 6-24 patients, within 2 years, study completion within 3 years at Mount Sinai Health System.
Primary Objective:
For Phase 1b to determine the safety and tolerability of Lamivudine with continued PD-(L)1 blockade for patients with relapsed/refractory metastatic solid tumors that have progressed on standard PD-(L)1 blockade.
For Phase 2, to determine the effect of adding lamivudine to PD-(L)1 blocki... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/22/2024
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Relapsed/Refractory Solid Tumors
First in Human, Dose Escalation Study of AN4005
Recruiting
Open-label, multicenter, phase 1 study to investigate the safety, tolerability, and PK of AN4005 in patients with advanced tumors. This study is a first-in-human, dose escalation study with the objective to establish the MTD and/or RP2D of AN4005.
Except for Dose Level 0 (50 mg), a traditional "3 + 3 design" will be utilized for dose finding with dose escalation and/or de-escalation as appropriate.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/22/2024
Locations: Montefiore Einstein Cancer Center, Bronx, New York
Conditions: Advanced Solid Tumor, Advanced Lymphoma
3517 - 3528 of 4476
When investigators decide to start a clinical trial, regulatory agencies such as the FDA and the IRB must review all plans and protocols to determine if the proposed trial is safe, ethical, and feasible. All clinical trials that recruit human participants have been reviewed and approved, and both non-paid and paid clinical research studies exist in New York.
After the study is approved the research team sets out to recruit volunteers who would like to participate in a clinical trial. Usually, volunteers are compensated for their time and travel expenses, and many paid clinical trials exist.
While one of the purposes of conducting clinical trials is testing the intervention on a large sample that would be representative of the general population, studies often have inclusion and exclusion criteria that outline who can and cannot participate. The inclusion criteria specifies the characteristics a participant must have in order to participate; for example, a liver cancer trial may have as an inclusion criteria that the participant must be a liver cancer patient.
On the other hand, the exclusion criteria outlines what type of individuals cannot participate; for example, a clinical trial testing a vitamin supplement in healthy individuals might want to disqualify participants who suffer from a serious condition and that can jeopardize the participant's ability to safely receive the experimental intervention. Due to safety concerns, pregnancy is often an exclusion criteria found in many studies.
In New York State, Columbia University and Mount Sinai Hospital are two of the largest research centers conducting clinical trials on a regular basis. As of this month, Columbia University is actively recruiting participants on at least 200 clinical trials from all phases, and Mount Sinai has over 500 active clinical trials.
Search Clinical Trials in New York by Condition
See All Conditions